Drug intelligence / Profile preview

HPP071

Development stage: Preclinical
Lead developer: vTv Therapeutics
Modality: Small Molecules

Overview

HPP071 (also known as HPP5033) is a preclinical small molecule drug candidate developed by vTv Therapeutics. It is designed to modulate the Nrf2/Bach1 pathway to treat oxidative and inflammatory conditions. Nrf2 (Nuclear factor erythroid 2-related factor 2) is a key transcription factor that regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation, while Bach1 (BTB and CNC homology 1) acts as a competitive inhibitor of Nrf2. By targeting this pathway, HPP071 aims to enhance the cellular antioxidant response and reduce inflammation.

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)BACH1 (BTB and CNC homology 1)

Beyond the preview

Go deeper on HPP071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPP071.

Explore the full profile